Finetech Laboratories Ltd.

Fine Tech Corporation

Isp Investments Inc.

Svc Pharma LP

Purdue Pharma L.p.

Cenes Limited

Other

Euro-Celtique S.a.

Par Pharmaceutical, Inc.

Finetech Pharmaceutical Ltd

Arie L Gutman

Gennady Nisnevich

Boris Tishin

Boris Pertsikov

Igor Zaltzman

Marina Etinger

Igor Rukhman

Irina Fedotev

Ram Khanolkar

Eleonora Shkolnik

Genady Nisnevich

Lev Yudovich

Lev Yudovitch

Gennadiy Nisnevich

Lev Judovich

Genadi Nisnevitch

Igor Zaltsman

Anton Shalimov

Maxim Sotrihin

Robert J Kupper

Alex Vilenski

Albay Agazade

Boris Pertzikov

Alexander Vilensky

Gennadi Nisnevich

Igor Rokhman

Igor Ruchman

Alex Vilensky

Igor Rochman

Gennadiy Nisnovich

Vladimir Kuznetsov

Gennady A Nisnevish

Gennady A Nisnevich

Boris M Pertsikov

Marina M Etinger

Irina M Fedotev

Methods for making trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition is prepared by allowing a composition comprising (&#xb1;)-&#x394;-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol based on the total amount of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

[object Object]

Methods for making trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI and trans-(+)-&#x394;-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI composition is prepared by allowing a composition comprising (&#xb1;)-&#x394;-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI composition comprising at least about 99% by weight of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol based on the total amount of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI having a purity of at least about 98% based on the total weight of cannabinoids.

Methods for making trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition is prepared by allowing a composition comprising (&#xb1;)-&#x394;)-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol based on the total amount of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

The invention provides a novel polymorphic form I of crystalline bimatoprost, method for preparation thereof and new crystalline intermediates in the preparation. This form I of crystalline bimatoprost is used in purification of crude bimatoprost and in storage of bimatoprost as active pharmaceutical intermediate. Use of the physical form of bimatoprost in the manufacture of a medicament is also disclosed.

Bimatoprost crystalline form I

The present invention provides, according to an aspect thereof, a novel process for the preparation of dronedarone [1] and pharmaceutically acceptable salts thereof. According to a preferred embodiment, the process comprises N-acetylating of p-anisidine or p-phenetidine with acetic anhydride, reacting of the obtained N-(4-alkoxyphenyl)acetamide with 2-bromohexanoyl chloride or bromide in the presence of aluminum chloride or bromide to obtain N-[3-(2-bromohexanoyl)-4-hydroxyphenyl]acetamide [6], converting the compound [6] into 2-butyl-5-benzofuranamine hydrochloride [12] and subsequently converting [12] into [1] or pharmaceutically acceptable salts thereof. In accordance with another aspect of this invention, there are provided novel intermediates, inter alia the novel compounds [6] and [12]. The novel intermediates of the present invention are stable, solid compounds, obtainable in high yields, which can be easily purified by crystallization and stored for long periods of time.

Process for the preparation of dronedarone

The present invention provides a new and efficient process for the preparation of the dexmethylphenidate hydrochloride with high optical purity, the process comprising: The present invention further provides salt of (R,R)-N-Boc-ritalinic acid with (S)-1-phenylethylamine as new intermediate in the preparation of dexmethylphenidate hydrochloride.

Process for the preparation of dexmethylphenidate hydrochloride

The invention provides a novel process for the preparation of prostaglandins and analogues thereof, and new crystalline intermediates in the process.

Process for the preparation of prostaglandin derivatives

The present invention provides a new and effective process for the synthesis of 17-phenyl-18,19,20-trinor-PGFand its derivatives, including the anti-glaucoma drugs Bimatoprost and Latanoprost. The benefit of the present invention rises inter alia from the fact that a major intermediate involved in the synthesis of the above compounds may be isolated from a mixture containing also an undesired isomer, by crystallization. In addition, the undesired isomer may be oxidized to give the starting compound, which is then recycled.

Process for the preparation of 17-phenyl-18,19,20-thinor-pgf 2a and its derivatives

The invention provides methods for preparing amorphous physical form of cabergoline, and solvate form A of cabergoline useful in the preparation of the first mentioned physical form. A method for treating a prolactin disorder with medicaments prepared from amorphous physical form of cabergoline and solvate form A of cabergoline is also disclosed.

Forms of cabergoline

The present invention provides a process for the preparation of threo-methylphenidate hydrochloride. According to a preferred embodiment, the process comprises the following steps:

Process for the preparation of threo-methylphenidate hydrochloride

Methods for making thebaine and an acid salt of thebaine are disclosed herein. In one embodiment, an acid salt of thebaine is made from codeinone or an acid salt of one or more of the following: 8-methoxy-&#x394;-dihydrothebaine, codeinone dimethyl ketal, and neopinone dimethyl ketal.

Methods for making thebaine or its acid salts

Disclosed is a process for the preparation of the anti-glaucoma drug Latanoprost, in good yield, in large amounts and with desired purity. Also disclosed are novel intermediates for the above process.

Process for the preparation of Latanoprost

Conjugation of 4,5-Epoxymorphinan-6-ols with Bromoglucuronides in the presence of Zinc containing compounds as activator under conditions capable of forming 4,5-Epoxymorphinan-6-oxyglucuronides is disclosed. This novel approach provides an efficient method for preparation of both anomers of 4,5-Epoxymorphinan-6-oxyglucuronides. The deprotected end products are useful as analgesic agents.

Process for preparation of 4,5-epoxymorphinan-6-oxyglucuronides

Growing community of inventors

Haifa, Israel

Arie L Gutman